*Supplemental file S4: Care Checklist Items per study*

| Care Checklist Items | | | Almagauer 2023 | Burghardt 2010 | Coupe 2005 | Garrido-Gomez 2012 | Gómez-Puerta 2008 | Hagiwara 2004 | Henning 2007 | Kastanis 2024 | Li 2023 | Macdonald 2006 | Martin 2010 | Rich 2018 | Sandri 2014 | Solarz 2017 | tenBroek 2014 | Weber 2016 | Wee 2013 | Wingstrand 1988 | Wohlrath 2013 | **Total** | **Percentage of studies that reported this item** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Title | 1 | The diagnosis or intervention of primary focus followed by the words "case report" | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 12 | 63% |
| Key Words | 2 | 2 to 5 key words that identify diagnoses or interventions in this case report, including "case report" | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 5.3% |
| Abstract | 3a | Introduction: What is unique about this case and what does it add to the scientific literature? | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 16 | 84.2% |
| (no references) | 3b | Main symptoms and/or important clinical findings | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 17 | 89.5% |
| | 3c | The main diagnoses, therapeutic interventions, and outcomes | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 16 | 84.2% |
| | 3d | Conclusion—What is the main "take-away" lesson(s) from this case? | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 17 | 89.5% |
| Introduction | 4 | One or two paragraphs summarizing why this case is unique (may include references) | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 17 | 89.5% |
| Patient Information | 5a | De-identified patient specific information | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 18 | 94.7% |
| | 5b | Primary concerns and symptoms of the patient | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 11 | 57.9% |

| | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 5c | Medical, family, and psycho-social history including relevant genetic information | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 9 | 47.4% |
| | 5d | Relevant past interventions with outcomes | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 5 | 26% |
| Clinical Findings | 6 | Describe significant physical examination (PE) and important clinical findings | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 18 | 94.7% |
| Timeline | 7 | Historical and current information from this episode of care organized as a timeline | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 17 | 89.5% |
| Diagnostic Assessment | 8a | Diagnostic testing (such as PE, laboratory testing, imaging, surveys) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 18 | 94.7% |
| | 8b | Diagnostic challenges (such as access to testing, financial, or cultural) | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 4 | 21.1% |
| | 8c | Diagnosis (including other diagnoses considered) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 18 | 94.7% |
| | 8d | Prognosis (such as staging in oncology) where applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5.3% |
| Therapeutic Intervention | 9a | Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 18 | 94.7% |
| | 9b | Administration of therapeutic intervention (such as dosage, strength, duration) | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 13 | 68.4% |
| | 9c | Changes in therapeutic intervention (with rationale) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 16 | 84.2% |
| Follow-up and Outcomes | 10a | Clinician and patient-assessed outcomes (if available) | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 11 | 57.9% |
| | 10b | Important follow-up diagnostic and other test results | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 9 | 47.4% |

| | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 10c | Intervention adherence and tolerability (How was this assessed?) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 7 | 36.8% |
| | 10d | Adverse and unanticipated events | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 13 | 68.4% |
| Discussion | 11a | A scientific discussion of the strengths AND limitations associated with this case report | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 31.6% |
| | 11b | Discussion of the relevant medical literature with references | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 17 | 89.5% |
| | 11c | The scientific rationale for any conclusions (including assessment of possible causes) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 18 | 94.7% |
| | 11d | The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 16 | 84.2% |
| Patient Perspective | 12 | The patient should share their perspective in one to two paragraphs on the treatment(s) they received | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0% |
| Informed Consent | 13 | Did the patient give informed consent? Please provide if requested | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 6 | 31.6% |
| | | Total per study (30 possible points) | 21 | 23 | 17 | 19 | 20 | 19 | 18 | 21 | 15 | 24 | 24 | 22 | 23 | 24 | 15 | 22 | 23 | 20 | 16 | | |
| | | Percentage of sufficiently reported items | 70% | 76.7% | 56.7% | 63.3% | 66.7% | 63.3% | 60% | 70% | 50% | 80% | 80% | 73.3% | 76.7% | 80% | 50% | 73.3% | 76.7% | 66.7% | 53.3% | | |

*Legend: item reported; item not reported; ≥ 50% reported items, ≥75% reported items*